The Inflation Reduction Act should take a different approach when it comes to authorized generic products, Sandoz US chief commercial officer Tim DeGavre has told Generics Bulletin.

Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.

Alvo group B2B unit Adalvo expects to file 30 decentralized procedures in Europe over the coming year as it expands its partnerships with Frontier Biopharma, Zentiva and Stada.

Hikma and Adalvo have struck a licensing deal that will see Hikma commercialize a “high value” nasal spray treatment for allergic rhinitis in the MENA region.